A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 255, Issue 3, 2017, Pages 463-473

  Callanan, David G ^a   Loewenstein, Anat ^b   Patel, Sunil S ^c   Massin, Pascale ^d   Corcóstegui, Borja ^e   Li, Xiao Yan ^f   Jiao, Jenny ^f   Hashad, Yehia ^f   Whitcup, Scott M ^g  

^a TEXAS RETINA ASSOCIATES   (United States)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c West Texas Retina   (United States)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Ophthalmology Department   (Spain)

^f ALLERGAN INC   (United States)

^g JULES STEIN EYE INSTITUTE   (United States)

Author keywords

Dexamethasone; Diabetic macular edema; Intravitreal; Noninferiority; Randomized clinical trial; Ranibizumab

Indexed keywords

DEXAMETHASONE; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; DRUG IMPLANT; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CATARACT; CENTRAL RETINAL THICKNESS; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE DURATION; DRUG EFFICACY; EYE PAIN; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; INTRAVITREAL IMPLANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUBCAPSULAR CATARACT; TREATMENT DURATION; VITREOUS FLOATERS; VITREOUS HEMORRHAGE; CLINICAL TRIAL; COMPLICATION; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG IMPLANT; EYE FUNDUS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; PATHOLOGY; RETINA MACULA LUTEA; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; VISUAL ACUITY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DEXAMETHASONE; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG IMPLANTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; YOUNG ADULT;

EID: 84986322649     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-016-3472-1     Document Type: Article

References (32)

1. Abcouwer SF (2013) Angiogenic factors and cytokines in diabetic retinopathy. J Clin Cell Immunol Suppl 1:1–12. doi:10.4172/2155-9899
2. Noma H, Mimura T, Yasuda K, Shimura M (2014) Role of inflammation in diabetic macular edema. Ophthalmologica 232:127–135. doi:10.1159/000364955
3. Agarwal A, Sarwar S, Sepah YJ, Nguyen QD (2015) What have we learnt about the management of diabetic macular edema in the antivascular endothelial growth factor and corticosteroid era? Curr Opin Ophthalmol 26:177–183. doi:10.1097/icu.0000000000000152
4. Jain A, Varshney N, Smith C (2013) The evolving treatment options for diabetic macular edema. Int J Inflamm 2013:689276. doi:10.1155/2013/689276
5. Erickson KK, Sundstrom JM, Antonetti DA (2007) Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis 10:103–117. doi:10.1007/s10456-007-9067-z
6. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S (2009) Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 116:73–79. doi:10.1016/j.ophtha.2008.09.037
7. Klaassen I, Van Noorden CJ, Schlingemann RO (2013) Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res 34:19–48. doi:10.1016/j.preteyeres.2013.02.001
8. Gupta N, Mansoor S, Sharma A, Sapkal A, Sheth J, Falatoonzadeh P, Kuppermann B, Kenney M (2013) Diabetic retinopathy and VEGF. Open Ophthalmol J 7:4–10. doi:10.2174/1874364101307010004
9. Park YG, Kim EY, Roh YJ (2014) Laser-based strategies to treat diabetic macular edema: history and new promising therapies. J Ophthalmol 2014:769213. doi:10.1155/2014/769213
10. Kiss S, Liu Y, Brown J, Holekamp NM, Almony A, Campbell J, Kowalski JW (2014) Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol 8:1611–1621. doi:10.2147/opth.s60893
11. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS, RISE and RIDE Research Group (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119:789–801. doi:10.1016/j.ophtha.2011.12.039
12. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A, RESTORE Study Group (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118:615–625. doi:10.1016/j.ophtha.2011.01.031
13. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33:2399–2405. doi:10.2337/dc10-0493
14. Wallick CJ, Hansen RN, Campbell J, Kiss S, Kowalski JW, Sullivan SD (2015) Comorbidity and health care resource use among commercially insured non-elderly patients with diabetic macular edema. Ophthalmic Surg Lasers Imaging 46:744–751. doi:10.3928/23258160-20150730-09
15. Wang K, Wang Y, Gao L, Li X, Li M, Guo J (2008) Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 31:1541–1546
16. Sohn HJ, Han DH, Kim IT, Oh IK, Kim KH, Lee DY, Nam DH (2011) Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol 152:686–694. doi:10.1016/j.ajo.2011.03.033
17. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, Welty D (2011) Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 52:80–86. doi:10.1167/iovs.10-5285
18. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group (2014) Three-years, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121:1904–1914. doi:10.1016/j.ophtha.2014.04.024
19. The CATT Research Group (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908. doi:10.1056/NEJMoa1102673
20. Kodjikian L, Souied EH, Mimoun G, Mauget-Faysse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G, GEFAL Study Group (2013) Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology 120:2300–2309. doi:10.1016/j.ophtha.2013.06.020
21. Berg K, Pedersen TR, Sandvik L, Bragadottir R (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122:146–152. doi:10.1016/j.ophtha.2014.07.041
22. Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, Baker CW, Berger BB, Bressler NM, Browning D, Elman MJ, 3rd Ferris FL, Friedman SM, Marcus DM, Melia M, Stockdale CR, Sun JK, Beck RW, Writing Committee for the Diabetic Retinopathy Clinical Research Network (2015) Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 314:2137–2146. doi:10.1001/jama.2015.15217
23. Augustin AJ, Kuppermann BD, Lanzetta P, Loewenstein A, Li XY, Cui H, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group (2015) Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmol 15:150. doi:10.1186/s12886-015-0148-2
24. Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arumi J, Mateo C, Corcostegui B (2014) Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica 231:141–146. doi:10.1159/000356413
25. Lazic R, Lukic M, Boras I, Draca N, Vlasic M, Gabric N, Tomic Z (2014) Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina 34:719–724. doi:10.1097/IAE.0b013e3182a48958
26. Panozzo G, Gusson E, Dalla Mura G (2015) Dexamethasone intravitreal implant for diabetic macular edema: indications for a PRN regimen of treatment. Eur J Ophthalmol 25:347–351. doi:10.5301/ejo.5000563
27. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, 3rd Ferris FL, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117:1064.e35–1077.e35. doi:10.1016/j.ophtha.2010.02.031
28. Querques G, Lattanzio R, Querques L, Triolo G, Cascavilla ML, Cavallero E, Del Turco C, Casalino G, Bandello F (2014) Impact of intravitreal dexamethasone implant (Ozurdex) on macular morphology and function. Retina 34:330–341. doi:10.1097/IAE.0b013e31829f7495
29. Khurana RN, Appa SN, McCannel CA, Elman MJ, Wittenberg SE, Parks DJ, Ahmad S, Yeh S (2014) Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies. Ophthalmology 121:67–71. doi:10.1016/j.ophtha.2013.06.033
30. Robinson MR, Whitcup SM (2012) Pharmacologic and clinical profile of dexamethasone intravitreal implant. Expert Rev Clin Pharmacol 5:629–647. doi:10.1586/ecp.12.55
31. Gutierrez-Benitez L, Millan E, Arias L, Garcia P, Cobos E, Caminal M (2015) Dexamethasone intravitreal implants for diabetic macular edema refractory to ranibizumab monotherapy or combination therapy. Arch Soc Esp Oftalmol 90:475–480. doi:10.1016/j.oftal.2015.04.003
32. Totan Y, Guler E, Guragac FB (2016) Dexamethasone intravitreal implant for chronic diabetic macular edema resistant to intravitreal bevacizumab treatment. Curr Eye Res 41:107–113. doi:10.3109/02713683.2014.1002048